portrait of smiling man stading in wooded areaportrait of smiling man stading in wooded areablue triangle graphic


Great Science
Deep Compassion
Real Impact

Leveraging our long-standing neuroscience
expertise to develop medicines that
make a difference.

Discover Alkermes

Featured News

July 17, 2024

Alkermes to Report Second Quarter Financial Results on July 24, 2024

Read more

June 03, 2024

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024

Read more

May 29, 2024

Alkermes to Participate in Two Upcoming Investor Conferences

Read more

See all press releases

Smiling woman standing in hallway at Alkermes office.

Responsible Growth

We think broadly about our commitment to responsible environmental stewardship, and strive to reduce the impact of our operations on the environment. We also seek to foster a collaborative culture that promotes the health, safety and well-being of our employees. 

View Corporate Responsibility report

Inspiring Inclusion

In celebration of International Women's Day, three senior female leaders at Alkermes reflected on their career journeys and their efforts to inspire inclusion.

Read the reflections

Man standing in lab coat with mask on in laboratory area at Alkermes.

Man sitting in front of green background at Alkermes office.

United in Purpose

Our employees are the foundation upon which our business is built. Their expertise, intelligence and creativity drive our innovation, and their passion and commitment to excellence are the cornerstone of our success. 

Explore career opportunities

R&D Pipeline 


We apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We are currently focused on developing these investigational candidates.

Click to view our interactive pipeline

  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Olanzapine and samidorphan

    • Schizophrenia and Bipolar I Disorder (Pediatric)

      Phase 3

    Overview

    Olanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.

    Clinical Trials

    Olanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.

  • ALKS 2680

    • Narcolepsy Type 1

      Phase 2

    • Narcolepsy Type 2

      Phase 1

    Overview

    ALKS 2680 is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy.

    Clinical Trials

    ALKS 2680 is currently being evaluated in the Vibrance-1 phase 2 study in adults with narcolepsy type 1. For more information about this study, please visit vibrancestudies.com (for U.S. audiences only) and clinicaltrials.gov/study/NCT06358950.

    ALKS 2680 was previously evaluated in a phase 1 study in healthy volunteers, and in adults with narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.

  • Orexin Agonists

    • Neuroscience Indications

      Discovery

    Overview

    Additional orexin 2 receptor agonists are in discovery for excessive daytime sleepiness disorders and other neuropsychiatric disorders.

These programs are investigating treatments or indications that have not received approval from a health authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a health authority. 






Last updated: April 2024

Careers

  We dare for progress every day. 
We take pride in our unique and compassionate spirit.
Our shared mission to make a real impact for others drives our purpose.
With collaboration at our core, we believe that anything is possible.

Working at Alkermes

Man with mask sitting in meeting talking to colleague at Alkermes.blue triangle graphic


Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We are driven to help advance innovation in hopes of providing additional treatment options for people living with complex and often difficult-to-treat diseases.